Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Tvardi Therapeutics, Inc. (TVRD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TVRD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $56.2
1 Year Target Price $56.2
| 4 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.72% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 242.26M USD | Price to earnings Ratio - | 1Y Target Price 56.2 |
Price to earnings Ratio - | 1Y Target Price 56.2 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 8.14 - 34.31 | Updated Date 07/26/2025 |
52 Weeks Range 8.14 - 34.31 | Updated Date 07/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Earnings Date
Report Date 2025-08-14 | When After Market | Estimate -1.11 | Actual 0.51 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 221232847 | Price to Sales(TTM) - |
Enterprise Value 221232847 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 9360900 | Shares Floating - |
Shares Outstanding 9360900 | Shares Floating - | ||
Percent Insiders 27.53 | Percent Institutions 2.76 |
Upturn AI SWOT
Tvardi Therapeutics, Inc.
Company Overview
History and Background
Tvardi Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing and commercializing small molecule inhibitors of the STAT3 pathway for the treatment of cancer and fibrosis. Founded in 2017, it has achieved clinical trial milestones for its lead compounds.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of STAT3 inhibitors for cancer and fibrotic diseases.
- Commercialization: Plans to commercialize its lead compounds upon regulatory approval.
Leadership and Structure
Details of the leadership team and organizational structure are not publicly available since Tvardi Therapeutics is privately held.
Top Products and Market Share
Key Offerings
- Tvardiu2019s lead compound: Tvardi's lead compound is a small molecule STAT3 inhibitor in Phase 2 clinical trials for various cancers and fibrotic diseases. Specific market share data is unavailable since they are pre-commercialization. Competitors include companies targeting similar pathways but none are specifically STAT3 inhibitors.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research intensive with focus on innovative drugs for unmet medical needs. It includes segments such as oncology, immunology and fibrosis. The rise in unmet needs are driving investment in the industry.
Positioning
Tvardi is positioning itself as a leader in STAT3 inhibition for cancer and fibrosis, focusing on a unique target with significant therapeutic potential. Their competitive advantage is the focus on a relatively underexplored pathway.
Total Addressable Market (TAM)
The TAM for STAT3 inhibitors in cancer and fibrosis could reach billions of dollars. Tvardi's positioning within this TAM is dependent on the successful completion of clinical trials and subsequent commercialization.
Upturn SWOT Analysis
Strengths
- Novel STAT3 inhibitor technology
- Strong preclinical and clinical data
- Experienced management team
- Focused therapeutic area
Weaknesses
- Limited financial resources
- High regulatory risk
- Limited commercialization experience
- Reliance on clinical trial success
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline to new indications
- Accelerated regulatory pathways
- Growing market demand for targeted therapies
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- No direct STAT3 inhibitor competitor exists at the same stage of clinical development. Indirect competitors include companies developing drugs in similar therapeutic areas.
Competitive Landscape
Since Tvardi is working on a very unique drug that is a STAT3 inhibitor, it does not have competition in the same arena. Tvardi would benefit from further progressing its product from phase 2 and beyond to start commercializing the drug.
Growth Trajectory and Initiatives
Historical Growth: Since it is a clinical stage private company, information on historical growth is not publicly available.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and commercial partnerships. Analyst estimates are not publicly available.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead compounds, securing funding for research and development, and expanding its patent portfolio.
Summary
Tvardi Therapeutics is a promising clinical-stage biopharmaceutical company focused on STAT3 inhibition for cancer and fibrosis. Its strength lies in its novel technology and strong preclinical data. Its private status and limited resources may be limiting factors. The company has significant growth potential if it can successfully navigate clinical trials and secure partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website (Tvardi Therapeutics, Inc.)
- Press releases
- Clinical trial data
- Industry reports
Disclaimers:
The information provided is based on publicly available sources and is for informational purposes only. It does not constitute financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tvardi Therapeutics, Inc.
Exchange NASDAQ | Headquaters Sugar Land, TX, United States | ||
IPO Launch date 2014-01-31 | CEO & Director Dr. Imran Alibhai Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 12 | Website https://tvarditherapeutics.com |
Full time employees 12 | Website https://tvarditherapeutics.com | ||
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.